[1]肖 扬,赵 威,张松涛,等.右美托咪啶与艾司洛尔治疗急性A型主动脉夹层的临床效果研究[J].医学信息,2021,34(18):132-134.[doi:10.3969/j.issn.1006-1959.2021.18.035]
　XIAO Yang,ZHAO Wei,ZHANG Song-tao,et al.The Clinical Effect of Dexmedetomidine and Esmolol in the Treatment ofAcute Type A Aortic Dissection[J].Medical Information,2021,34(18):132-134.[doi:10.3969/j.issn.1006-1959.2021.18.035]
点击复制

右美托咪啶与艾司洛尔治疗急性A型主动脉夹层的临床效果研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年18期
页码:
132-134
栏目:
临床研究
出版日期:
2021-09-18

文章信息/Info

Title:
The Clinical Effect of Dexmedetomidine and Esmolol in the Treatment ofAcute Type A Aortic Dissection
文章编号:
1006-1959（2021）18-0132-03
作者:
肖 扬; 赵 威; 张松涛; 尹 文
空军军医大学第一附属医院急诊科，陕西 西安 710032
Author(s):
XIAO Yang; ZHAO Wei; ZHANG Song-tao; YIN Wen
Emergency Department,the First Affiliated Hospital of Air Force Military Medical University,Xi’an 710032,Shaanxi,China
关键词:
主动脉夹层; 艾司洛尔; 右美托咪啶
Keywords:
Aortic dissection; Esmolol; Dexmedetomidine
分类号:
R654.2
DOI:
10.3969/j.issn.1006-1959.2021.18.035
文献标志码:
A
摘要:
目的 分析右美托咪啶与艾司洛尔联合治疗急性A型主动脉夹层的临床效果。方法 选择2019年1月-2020年12月就诊于西京医院急诊科的急性A型主动脉夹层患者共120例。在给予艾司洛尔控制血压、心率基础上，根据是否用右美托咪啶分为右美托咪啶组（Dex组）57例，非右美托咪啶组（Non-Dex组）63例。比较两组治疗前后不同时间的平均动脉压（MAP）和心率（HR）达标情况，分析术前及术后2周死亡率。结果 Dex组T1、T2、T4、T6时HR、MAP均低于T0（P＜0.05）；Non-Dex组T2、T4、T6时HR、MAP均低于T0（P＜0.05）；Non-Dex组T0与T1时HR比较，差异无统计学意义（P＞0.05）；Dex组6 h的MAP和HR达标率分别为87.71%、89.47%，高于Non-Dex组的68.33%、65.07%（P＜0.05）；Dex组的MAR、HR平均达标时间短于Non-Dex组（P＜0.05）；Dex组总死亡率为10.53%，低于Non-Dex组的25.40%（P＜0.05）；Dex组术前及总死亡率分别为7.02%、10.53%，均低于Non-Dex组的20.63%、25.40%（P＜0.05）；Dex组术后2周死亡率为3.77%，低于Non-Dex组的6.00%，但差异无统计学意义（P＞0.05）。结论 右美托咪啶联合艾司洛尔可更加有效地控制急性主动脉夹层患者血压、心率，缩短血压、心率达标所需时间，并降低主动脉夹层患者围手术期死亡率。
Abstract:
Objective To analyze the clinical effect of dexmedetomidine and esmolol in the treatment of acute type A aortic dissection.Methods A total of 120 patients with acute type A aortic dissection who were admitted to the emergency department of Xijing Hospital from January 2019 to December 2020 were choiced. On the basis of giving esmolol to control blood pressure and heart rate, according to whether dexmedetomidine was used or not, 57 cases were divided into dexmedetomidine group (Dex group) and non-dexmedetomidine group (Non-Dex group) 63 example.The mean arterial pressure (MAP) and heart rate (HR) compliance status at different times before and after treatment were compared between the two groups, and the mortality rate before and 2 weeks after the operation was analyzed.Results HR at T1, T2, T4 and T6 in dex group was lower than T0(P＜0.05). HR and map in non DEX group at T2, T4 and T6 were lower than T0(P＜0.05); There was no significant difference in HR between T0 and T1 in non DEX group (P＞0.05);The 6 h MAP and HR compliance rates of the Dex group were 87.71% and 89.47%, respectively, which were higher than those of the Non-Dex group of 68.33% and 65.07%(P＜0.05);The average MAR and HR compliance time of the Dex group was shorter than that of the Non-Dex group(P＜0.05);The total mortality rate in the Dex group was 10.53%, which was lower than 25.40% in the Non-Dex group(P＜0.05); The preoperative and total mortality in dex group were 7.02% and 10.53% respectively, which were lower than 20.63% and 25.40% in Non-Dex group (P＜0.05); The 2-week mortality in dex group was 3.77%, which was lower than 6.00% in Non-Dex group, but the difference was not statistically significant (P＞0.05).Conclusion Dexmedetomidine combined with esmolol can more effectively control the blood pressure and heart rate of patients with acute aortic dissection, shorten the time required for blood pressure and heart rate to reach the standard, and reduce the perioperative mortality of patients with aortic dissection.

参考文献/References:

[1]Guné H,Larsson M,Nozohoor S,et al.Impact of ABO blood group on bleeding complications after surgery for acute type A aortic dissection[J].Blood Coagul Fibrinolysis,2021,32(4):253-258.[2]Mussa FF,Horton JD,Moridzadeh R,et al.Acute Aortic Dissection and Intramural Hematoma: A Systematic Review[J].JAMA,2016,316(7):754-763.[3]庄熙晶,高洋,高峰,等.地尔硫卓与美托洛尔对急性主动脉夹层患者血压和心率的控制效果研究[J].中国全科医学,2016,19(S1):45-48.[4]Marroush TS,Boshara AR,Parvataneni KC,et al.Painless Aortic Dissection[J].Am J Med Sci,2017.354(5):513-520.[5]Koechlin L,Macius E,Kaufmann J et al.Aortic root and ascending aorta dimensions in acute aortic dissection[J].Perfusion,2020,35(2):131-137.[6]Soliman R,Zohry G.The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery[J].Ann Card Anaesth,2016,19(4):606-613.[7]中国医师协会心血管外科分会大血管外科专业委员会.主动脉夹层诊断与治疗规范中国专家共识[J].中华胸心血管外科杂志,2017,33(11):641-654.[8]Cifani N,Proietta M,Tritapepe L,et al.Stanford-A acute aortic dissection, inflammation, and metalloproteinases: a review[J].Ann Med,2015;47(6):441-446.[9]Aggarwal B,Raymond CE.Therapeutic goals in patients with acute aortic dissection: management before surgery[J].J Am Coll Cardiol,2015,65(15):1599-1600.[10]Goldfinger JZ,Halperin JL,Marin ML,et al.Reply: therapeutic goals in patients with acute aortic dissection: management before surgery[J].J Am Coll Cardiol,2015,65(15):1601-1602.[11]Franco V,Bialer M,Perucca E.Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research[J].Neuropharmacology,2021(185):108442.[12]Franco V,Perucca E.Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy[J].Drugs,2019,79(13):1435-1454.[13]Soliman R,Zohry G.The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery[J].Ann Card Anaesth,2016,19(4):606-613.[14]Chen SL,Chai YF,Wang ZH,et al.Effects of dexmedetomidine on heart rate control and pre-operative outcome in patients with acute aortic dissection: a propensity-matched analysis[J].Ann Palliat Med,2020,9(5):2886-2894.[15]Ma J,Zhang XL,Wang CY,et al.Dexmedetomidine alleviates the spinal cord ischemia-reperfusion injury through blocking mast cell degranulation[J].Int J Clin Exp Med,2015,8(9):14741-14749.[16]Zhang J,Zhang X,Qian H,et al.[Dexmedetomidine alleviates cognitive dysfunction induced by tibial fracture in rats][J].Journal of Southern Medical University,2019,39(3):292-297.

相似文献/References:

[1]周 阎,向道康.DeBakeyⅠ型主动脉夹层的诊疗现状[J].医学信息,2020,33(06):47.[doi:10.3969/j.issn.1006-1959.2020.06.014]
　ZHOU Yan,XIANG Dao-kang.Status of Diagnosis and Treatment of DeBakey Ⅰ Aortic Dissection[J].Medical Information,2020,33(18):47.[doi:10.3969/j.issn.1006-1959.2020.06.014]
[2]曾岸轲,韦亚宁,张怡蒂,等.3D打印技术在主动脉夹层中的应用进展[J].医学信息,2024,37(05):188.[doi:10.3969/j.issn.1006-1959.2024.05.036]
　ZENG An-ke,WEI Ya-ning,ZHANG Yi-di,et al.Application Progress of 3D Printing Technology in Aortic Dissection[J].Medical Information,2024,37(18):188.[doi:10.3969/j.issn.1006-1959.2024.05.036]

更新日期/Last Update: 1900-01-01